Last summer’s NotPetya ransomware attack should have been a wake-up call for the pharmaceutical industry. It infected organizations worldwide, including Merck. Employees at that pharmaceutical giant found manufacturing, research, sales, packaging, and formulations operations were locked. Even one month after the June 21 attack, some company operations were still recovering.
The magnitude of the attack jolted pharma executives, who began to understand the extent of the oncoming threats. Yet, rather than meaningfully enhancing cybersecurity, most resigned themselves to being hacked and turned their attention to driving innovation.